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ABSTRACT
The human pluripotent stem cell registry (hPSCreg),
accessible at http://hpscreg.eu, is a public registry
and data portal for human embryonic and induced
pluripotent stem cell lines (hESC and hiPSC). Since
their first isolation the number of hESC lines has
steadily increased to over 3000 and new iPSC lines
are generated in a rapidly growing number of lab-
oratories as a result of their potentially broad ap-
plicability in biomedicine and drug testing. Many of
these lines are deposited in stem cell banks, which
are globally established to store tens of thousands
of lines from healthy and diseased donors. The Reg-
istry provides comprehensive and standardized bi-
ological and legal information as well as tools to
search and compare information from multiple hPSC
sources and hence addresses a translational re-
search need. To facilitate unambiguous identifica-
tion over different resources, hPSCreg automatically
creates a unique standardized name for each cell
line registered. In addition to biological information,
hPSCreg stores extensive data about ethical stan-
dards regarding cell sourcing and conditions for ap-
plication and privacy protection. hPSCreg is the first
global registry that holds both, manually validated
scientific and ethical information on hPSC lines, and
provides access by means of a user-friendly, mobile-
ready web application.
INTRODUCTION
The research landscape for human pluripotent stem cells
(hPSC) is changing rapidly. The establishment of human
embryonic stem cells (hESC) in 1998 (1) and human in-
duced pluripotent stem cells (hiPSC) in 2007 (2) has pro-
vided new tools for cell biology, regenerative medicine, dis-
ease modeling and drug and toxicity testing. The establish-
ment of thousands of humanESC and iPSC lines, deposited
in multiple national and international cell banks, aims to
match the growing demands from these fields. Together with
the increasing demand for hPSC lines, technologies for their
characterization and modification, including omics, func-
tional cell assays and tools for geneticmodification, are con-
stantly being improved. At the same time, higher standards
for characterization have to be fulfilled. A registry for hu-
man PSC needs to provide an inventory of available cell
lines throughout the diverse resources together with val-
idated characterization data and information on cell line
origin and application. Since applicability depends on the
donor consent, e.g. regarding access to genetic data and
commercial use, information on the ethical and regulatory
environment under which these cells were obtained is highly
relevant.
The Human Pluripotent Stem Cell Registry (hPSCreg;
http://hpscreg.eu), established in 2007 with funding from
the European Commission, originally aimed to provide
transparency and comparability as well as management of
ethical compliance in the dynamic yet controversial field
of human ESC research (3,4). With the establishment of
human iPSC, the registry was expanded and the database
and user interface completely rebuilt to allow for registra-
tion of a broad set of human PSC-line related data. Where
possible, the use of ontology and other standard terms was
implemented to annotate lines. Importantly, registration is
accompanied by automatic assignment of a unique name
for each hPSC line, based on a standardized nomenclature.
Availability of lines and regulatory background for their use
is visualized in an interactive world map. All information is
validated before publication, following a standardized in-
ternal process.
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Currently there are 759 cell lines from 25 different coun-
tries registered in hPSCreg, thereof 683 hESC and 76 hiPSC
lines. hPSCreg registers hPSC lines of existing cell banks
and registries, including the European Bank of induced
pluripotent Stem Cells (EBiSC), the Human iPSC Initiative
(HipSci), WiCell Research Institute, the Korean Stem Cell
registry and NIMH stem cell center at Rutgers. An exem-
plary pipeline established with EBiSC requires registration
of an hiPSC line in hPSCreg, which assigns a name together
with a BioSample ID (https://www.ebi.ac.uk/biosamples/,
(5)) via the European Bioinformatics Institute (EMBL-
EBI) to facilitate immediate identification and data access
by EBiSC with unique identifiers from donor to cell line,
batch or lot level.
CELL DATA REGISTRATION AND MANAGEMENT
Registration
Data acquisition is achieved by user-initiated registration of
a cell line (Figure 1). hPSCreg developed and implemented
an online registration tool of more than 740 possible data
fields, which allows in-depth provision of information on
each registered cell line (Table 1). The data fields were iden-
tified in close collaboration with the generators and users
of human PSC lines. Registration information includes data
about the provider of the data, characteristics of the donor
of the tissue or cells used to generate hPSC-lines, the meth-
ods used to derive a cell line from the donated tissues, the
cultivation conditions used for the hPSC-line and details on
their phenotype and genotype. Donor related data includes
information on the consenting process used for tissue dona-
tion and the content of the consented data use.
The registration is divided into three levels of data provi-
sion (Table 2), which contain (i) mandatory information to
automatically assign a unique name to the line, (ii) manda-
tory data on a minimal set of information to provide evi-
dence that a line is pluripotent and has been derived within
an appropriate ethical framework and (iii) non-mandatory
information beyond the minimal dataset to refine and ex-
pand donor and cell line specific information, for example
with genotyping data.
Information required for applying a standardized
nomenclature to automatically assign a unique name
and identifier for each cell line is based on the system
proposed by Luong et al. (6), with modifications (Table 2).
It contains a unique acronym to identify the provider
institute, a cell type descriptor such as ‘e’ for hESC and
‘i’ for hiPSC, a unique alphanumerical donor name and
information on the relatedness of a cell line to a specific
donor, e.g. whether the cell line is another clone from
the same donor or a cell line is a subclone of another
line. The implemented nomenclature allows in theory the
assignment of 12 356 604 cell line generators to name
46 655 different donors, for each donor 26 different cell
lines, for each cell line 1330 subclones and hence can
provide more than 3 billion cell lines per provider. The
Registry provides an application program interface (API)
at http://hpscreg.eu/api/create name to programmatically
generate new hPSCreg cell line names, which is especially
important for companies and research project that generate
large numbers of new hPSC lines, which can be named with
Table 1. Data fields available for hESC and hiPSC registration
Number of fields
Cell type hiPSC hESC





Donor information 82 66




Cell line information 625 607















The online registration tool provides more than 740 possible data fields
for hPSC, which allows in-depth provision of detailed information on each
registered cell line.
a standard hPSCreg-name while they are being generated.
A detailed documentation about this functionality is
available at http://hpscreg.eu/about/naming-tool.
Minimal information is mandatory to assess whether a
cell line is pluripotent (Table 2). It requires evidence that
at least four generally accepted pluripotency marker genes
are expressed and that the cells can differentiate into cells
of each of the three germ layers (endoderm, ectoderm and
mesoderm). In addition, minimal information requires ev-
idence that a prudent and ethical process was followed for
the consenting of the embryo or tissue donors. The required
information is naturally different between human ESC and
iPSC lines, but generally asks for information on ethics
approvals, the consenting process and the provisions pro-
vided in the consent form signed by the donor. Finally, the
provider must inform about applicable restrictions for the
use of the cell line for research. Altogether, up to 52 fields
are mandatory for registration of a line.
Additional registration information includes phenotype
and genotype information of the tissue donors, derivation
and cultivation details and genotype information of the cell
line. These data fields are not mandatory, but provide infor-
mation important for potential users.
Where applicable, terms from existing ontologies are used
this includes for example descriptions of diseases, cell types
and tissues. To easily find the right ontology term, the cor-
relating fields in the online registration form are linked to
CellFinder (http://www.cellfinder.org, (7)), where users can
search terms across a broad range of ontologies and retrieve
ontology terms (8) alongside detailed descriptions to fos-
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Figure 1. Registration process for a hPSC line. First, to access the cell line registration, users have to sign-up for an account (1a). A valid generator
institution with a unique two to five letter acronym has to be registered or chosen from a list of already registered institutions (1b). To register a single cell
line, users need to enter the minimum data (2a), allowing the creation of a unique hPSCreg name (2b) according to the hPSCreg nomenclature. Following,
detailed cell line information (2c) has to be entered. To finally submit, a set of 52 mandatory fields have to be completed (2d). An international expert panel
will validate the given information about the submitted cell line (3a). After successful validation, the cell line is published publicly on hPSCreg’s website
(3b).
ter confidence in term selection. To aid data quality and
ease of registration, hPSCreg implemented few literal text
inputs and strongly relies on predefined field values. Exper-
imental protocols and images can be uploaded to provide
even richer descriptions. Omics datasets (e.g. from cDNA
microarrays, RNA-Seq, CHiP-Seq) deposited elsewhere are
linked to cell lines using the appropriate database identifier
(e.g. BioSample ID, GEO ID).
To reduce uncertainty and accidental errors during regis-
tration, hPSCreg provides extensive help texts for each in-
put.
Validation
The quality of data available on hPSCreg and its ethi-
cal acceptability is of utmost importance. We have estab-
lished strict criteria to ensure high quality through an open,
fair and scientifically rigorous process. This process puts a
strong focus on standardization of data input to streamline
comparison and validation of data on cell lines from differ-
ent sources.
To control data accuracy, hPSCreg uses a three-step reg-
istration system (Figure 1). First, prior to cell line registra-
tion, the user has to sign up for an account in order to sup-
ply contact details. This is crucial in order to provide full
provenance and to allow communication between data cu-
rators and users. After hPSCreg has verified that the appli-
cant is bona fide provider (i.e. from a recognized research
organization) the account will be validated. In the second
step, the approved users enter cell line related information.
After at least the mandatory nomenclature and minimal in-
formation has been provided, the provided information gets
manually checked by the hPSCreg data curators. In case of
incomplete information or plausibility issues, the provider
is contacted for clarification. In the last validation step, the
hPSCreg Committee of National Representatives (CNR) is
informed and can provide additional feedback on the valid-
ity of the data. Only cell lines validated by the hPSCreg data
curators and the CNR will be made available to the public.
Additional validation can be provided by feedback from
users. While this is in principle possible already by editing
information provided for a cell line in hPSCreg’s registra-
tion tool followed by manual validation, the feedback pro-
cess will be expanded and refined in future versions of the
Registry.
Access
To ease data access, retrieval and understanding, hPSCreg
follows a user-centered design approach by implementing
an easy-to-use, mobile-friendly and aesthetically pleasing
web application. The application’s goal is to help users find
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Table 2. Mandatory fields for the nomenclature and minimal data for registration of an hPSC line in hPSCreg
Assignment of a standardized name is the initial step to register a cell line. The name is generated automatically based on the given information. For
full registration minimal registration information is required that it can be validated that the line is pluripotent and obtained under a regulated ethical
framework. Furthermore, the provision of some details on the donor and cell line generation. Non-mandatory fields are not shown in the table. These are
provided to expand on the information provided for each cell line.
cell lines and related data as quickly as possible. The inter-
face design is kept at a minimum with focus on content, of-
fering three ways of data discovery: searching, browsing and
visual exploration.
Text-based searching is designed to be simple but pow-
erful and is omnipresent in hPSCreg, i.e. a search can be
started from any page. Search results are ranked according
to their relevance by default but can be sorted by name or
date as well. The result list shows the hPSCreg name along-
side a list of alternative cell line identifiers, the contact insti-
tution, the derivation country and date, diseases associated
with the specific cell line. Furthermore, the interface imple-
ments instantaneous faceted search to limit the search space
to cell type, countries, diseases and derivation date.
In terms of browsing, hPSCreg provides the possibility to
access all available cell lines via facet filter enabled lists just
like the search results. Furthermore, cell line provider and
hPSC research projects can be browsed through searchable,
sortable and filter-enabled lists. For example, providers can
be narrowed down by role, i.e. cell line generator, owner or
distributor. As projects in which a particular cell line is used
can be registered, and all EU-funded projects using hPSC
must be registered at hPSCreg (9), these can be sorted al-
phabetically as well as by start- or end-date of the project.
Lastly, hPSCreg offers a list of countries with information
regarding registered cell lines, research projects and legal in-
formation.
To ease summarizing of available data in hPSCreg and the
current state of hESCand hiPSC research around theworld,
an interactive colored world map has been implemented
(Figure 2), visualizing the absolute and log-transformed dis-
tribution of registered hESC and hiPSC lines as well as the
current state of ES cell research related legislation per coun-
try. The world map is draggable and zoomable and shows
 at Freie U







Nucleic Acids Research, 2016, Vol. 44, Database issue D761
Figure 2. Interactive world map. Exploration of the worldwide distribution of registered cell lines and country-wise legalization: (A) shows the world wide
log-transformed distribution of registered hPSC lines in hPSCreg. Colors range from dark gray (least cell lines registered) to saturated red (most cell lines
registered). Countries without any registered cell line are colored in light gray. Note that in the printed version of this article colors are shown in gray
scale. (B) Shows a zoomed view of Europe, displaying legal information by a five-grade color system. The coloring is an approximation of the exact legal
state. More details are available on the country specific pages which are linked to the map.
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country-specific information upon selection by a mouse-
click or finger-tab, which is cross-linked to detailed pages.
To improve hPSC line identification and minimize ambi-
guities, a simple yet semantically meaningful system for in-
formation retrieval is needed. A semantic uniform resource
locator (URL) for every registered and validated cell line
is provided by hPSCreg. Such a persistent URL will not
change over time, allowing their use as uniform resource
identifiers (URI) in future application ontologies. Seman-
tic URLs in hPSCreg follow the schema: 〈ORGANIZATI
ON〉/〈RESOURCE〉/〈IDENTIFIER〉. Hereby, the organi-
zation and resource will be http://hpscreg.eu and cell-line
respectively, while the identifier is a standardized hPSCreg
name. For example, qualitative meta information of the
hESC line WAe009-A (hPSCreg-derived standard name;
also called WA09 or H9) can be accessed at http://hpscreg.
eu/cell-line/WAe009-A.
Access to certain information falls under a managed ac-
cess code, based on the consent provided by the original tis-
sue donor to protect privacy. This includes genetic informa-
tion and some clinical data, which may be used to identify
the donor (10).Managed access for genetic data is only pos-
sible through data access committees, which are entitled to
permit access to cell-line specific data deposited in central
databases such as the European Genome-phenome Archive
(EGA). Genetic data that are not under a managed access
policy are directly available in hPSCreg, including for ex-
ample human leukocyte antigen (HLA) and short tandem
repeats (STR) data.
IMPLEMENTATION
The hPSCreg web application’s architecture can best be de-
scribed as a four-tier system, consisting of a front-end ap-
plication, i.e. user interface (UI), a middleware server-side
application, a large set of specialized web-services and data
stores.We follow themicro-services architecture pattern, for
maximumflexibility, helping hPSCreg to scale well in the fu-
ture. The front-end application, implemented using cutting
edge HTML5, CSS3 and JavaScript technologies, commu-
nicates with a PHP-based middleware application, running
on an Apache web server. The middleware securely handles
the communication between UI and a variety of specialized
Java-based micro web-services. These micro web-services
process, send and retrieve data from the data stores. Data
is simultaneously stored in a MySQL database manage-
ment system and Elasticsearch. MySQL databases, act as
themain data storage, while Elasticsearch enables aGoogle-
like search experience. LDAP is used for authorizing users
and managing groups.
The Registry has implemented a partnership with the Eu-
ropean bank of induced pluripotent stem cells (EBiSC) and
is used by this bank as a depositors’ portal for the regis-
tration of iPSC-lines for deposition in EBiSC. EBiSC is us-
ing hPSCreg’s registration facility and nomenclature system
to achieve standardized data provision and unambiguous
naming of all lines. In addition, hPSCreg provides, through
an API with the European Bioinformatics Institute (EBI),
a BioSamples ID to each line registered for EBiSC. The BS-
ID provides a unique identifier for aggregation of any sam-
ple related to the cell line, for example the donor, RNA,
differentiated cells, lots and batches derived from the line,
as well as relationships between samples such as ‘derived
from’. Hence the implementation of a standard registration
tool, a unique standard name and a BS-ID provides data
traceability between different banks and institutions, and
comparability down to the sample and lot level.
DISCUSSION
The human pluripotent stem cell registry provides compre-
hensive and cell line specific information on human PSC-
lines around the world. In contrast, most other registries
are restricted to banks or to specific uses of lines such as
the restriction to lines eligible for funding by NIH funds in
the NIH registry (http://grants.nih.gov/stem cells/registry/
current.htm), or restricted to national cell lines, for exam-
ple in Korean PSC Registry (11). Federated systems, such
as eagle-i (12) provide links to different resources harbor-
ing PSC lines, but the information provided is not as stan-
dardized and comprehensive as what can be provided in a
centralized database such as hPSCreg. Hence, hPSCreg is
unique as a global registry providing comprehensive scien-
tific and ethical information on human PSC lines. The task
of defining minimal standards for human PSC line charac-
terization is thus one of the key elements of hPSCreg and
has been addressed via standard nomenclature and mini-
mal PSC criteria. Moreover, hPSCreg is the only registry,
which centrally delivers information on lines from multiple
providers and banks facilitating effective use of the avail-
able resources. One of the key requirements for facilitating
comparative evaluation over so many and diverse reposito-
ries are unique identifiers and standard criteria for registra-
tion and assessment - despite a large variety of experimental
procedures used. We expect that in the ongoing consolida-
tion process of the field, standards and protocols will be es-
tablished and eventually dominate especially sensitive areas
such as application of human PSC for clinical or drug test-
ing applications. These areas require adherence to standards
and guidelines defined also by regulatory agencies. The reg-
istry will adjust its registration formats accordingly and we
expect to stratify the required fields further, for example to
accommodate and validate human PSC lines suitable for
clinical application.
In addition, the regulatory landscapewas and still is char-
acterized by diverse ethical conceptions on hPSC deriva-
tion and usage, which continuously requires transparency
about the cell’s origins, compliance with ethical standards
and information about availability of the cells to researchers
(13). The registry supports harmonizing the standards for
obtaining informed consent for tissue donation and use,
for example by codifying ethics information. A first step is
the ethics registration form within hPSCreg’s registration
tool. Similarly, the development of suitable ontologies for
information enrichment is a future task. While ontology
and standardized terms are already being used in hPSCreg,
many areas are not yet covered. Collaborative efforts for ex-
ample between eagle-i and hPSCreg on the development of
ontologies, informed consent codification and clinical data
standards will be useful to enhance resource usage, compa-
rability and applicability of cell lines.
 at Freie U







Nucleic Acids Research, 2016, Vol. 44, Database issue D763
One increasingly important application of human PSC
is their use in drug efficacy studies, based on genetically
stratified cohorts of individualized cell lines. This requires
access to genetic data from the cells and is currently han-
dled via data access committees. This elaborate process is
prohibitive for the design of these kinds of studies aim-
ing to use cells from different sources. Hence, there is a
need to develop specific access protocols for potentially sen-
sitive genetic data, which adheres to the standards estab-
lished by the Global Alliance for Genomics and Health
(http://genomicsandhealth.org).
CONCLUSION AND OUTLOOK
hPSCreg was established in 2007 as the European human
embryonic stem cell registry and is supported by the Euro-
pean Commission. Its initial goal to provide transparency
to the field of stem cell research and to establish ethi-
cal standards has been extended to cover all fields of hu-
man pluripotent stem cell research. The registry now pro-
vides comprehensive scientific and ethical information on
all hPSC lines and provides these to scientists, regulators,
lawmakers and the general public. Future implementations
will include integration of standards and validation tools
for clinical grade human PSC, the registration of clinical
trials using stem cells as well as the provision of APIs for
programmatic access to hPSCreg’s data and registry. An
option for downloading certain parts of hPSCreg is cur-
rently tested.The registry will be sustained through further
European and international funding, which will allow it to
gradually develop additional tools, includemore focused in-
formation on cell types derived from human PSC, disease-
specific lines and implementation of feedback as well as cus-
tomized data display and documentation tools.
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